Pharma Cold Chain Logistics Best Practices 2025 Guide
Mis à jour en novembre 26 2025
Pharma cold chain logistics best practices protect life saving medicines and vaccines from temperature fluctuations that can ruin their potency. Dans 2025 the global cold chain logistics market is booming—forecast to surge from about NOUS $324.85 milliards en 2024 à NOUS $862.33 milliards 2032—because biologics, advanced therapies and obesity treatments depend on controlled temperatures. Yet up to 20 % of temperature sensitive drugs are compromised in transit and nearly 50 % de vaccins are wasted due to poor cold chain management. If you handle pharmaceuticals, you need a robust cold chain strategy that ensures products remain within their required ranges (often 2–8 °C), complies with regulations like GDP/GMP and the Loi sur la sécurité de la chaîne d'approvisionnement en médicaments (DSCSA), and leverages emerging technologies such as IoT sensors, AI analytics and blockchain for real time visibility. This guide answers your questions and provides pharma cold chain logistics best practices to help you safeguard medicines, reduce waste and stay compliant in 2025.
Why are pharma cold chain logistics best practices essential? – We explain the stakes for patient safety and financial integrity, and why 2–8 °C matters for most vaccines and biologics.
Which regulations govern pharma cold chain logistics in 2025? – Learn about GDP, GMP, DSCSA and regional frameworks and what they mean for your operations.
What technologies are transforming cold chain logistics? – Explore IoT sensors, AI route optimisation, blockchain, solar powered storage and automation.
How do you choose packaging and equipment? – Compare insulated containers, expéditeurs de palettes, matériaux à changement de phase, cryogenic shippers and smart packaging.
How can you build a compliant and resilient cold chain? – Follow our best practice checklist for manufacturing, stockage, transport et distribution.
What trends and market developments will shape 2025? – Understand the growth of biologics, sustainability pressures and the push for end to end visibility【542920472744014†L621-L699】.
What are common cold chain questions? – Find practical answers to FAQs about temperature ranges, excursions, compliance and technology.
Why are Pharma Cold Chain Logistics Best Practices Essential?
Temperature control protects product potency and patient safety. Vaccines and biologic therapies lose effectiveness when exposed to unsuitable temperatures; Par exemple, traditional vaccines must stay between 2 °C et 8 °C, some biologics require –20 ° C storage and gene or cell therapies demand –80 °C à –150 °C cryogenic conditions. Brief excursions can render medicines ineffective. Studies estimate up to 20 % of temperature sensitive drugs are compromised during transit, costing billions and risking patient health. With the pharmaceutical cold chain market expected to reach NOUS $6.6 milliards en 2025 et NOUS $9.6 milliards 2035, ensuring reliable cold chain logistics is a competitive necessity.
Financial and reputational stakes are high. Vaccine spoilage wastes almost 50 % of doses worldwide, and cold chain failures can trigger recalls, regulatory penalties and reputational damage. Maintaining a dependable cold chain preserves product integrity, supports compliance and protects your brand.
Les exigences de température varient selon le produit. Understanding specific ranges helps you choose appropriate equipment and packaging. The table below summarises common categories:
Temperature Categories and Benefits
| Catégorie de produit | Plage de température typique | Pourquoi ça compte | Avantage pratique |
| Vaccins standards | 2–8 ° C (36–46 °F) | La plupart des vaccins (grippe, hépatite, VPH) remain potent only within this refrigerated range | Ensures immunity and avoids costly revaccination |
| Biologique & peptides | 2–8 ° C; some require –20 °C | Anticorps monoclonaux, insulin and GLP 1 agonists degrade quickly outside controlled refrigeration | Maintains drug efficacy and reduces patient risks |
| Gene & thérapies cellulaires | –80 °C à –150 °C (cryogénique) | CAR T therapies and viral vectors require ultra cold storage; temperatures can reach –190 °C | Preserves living cells and maximises therapeutic success |
| Température ambiante contrôlée (CRT) médicaments | 15–25 ° C (59–77 °F) | Many oral drugs and some biologics can be stored at CRT but need monitoring to avoid heat or freeze damage | Avoids product degradation and reduces energy costs |
| Obesity medications | 2–8 ° C | GLP 1 receptor agonists like Wegovy and Mounjaro require refrigeration | Supports growing patient demand and reduces waste |
Practical Tips and Real World Insights
Always confirm manufacturer ranges. Never assume one range fits all products; verify each drug’s specification.
Use medical grade equipment. Purpose built refrigerators and freezers deliver uniform temperature; avoid dormitory style units that may freeze vaccines.
Minimise door openings. Frequent door openings introduce warm air and cause fluctuations.
Label storage areas. Clear labels such as “2–8 °C medicines” reduce handling errors.
Record everything. Document every temperature measurement; accurate records support audits and help identify deviations.
Exemple du monde réel: Pendant le déploiement du COVID 19, clinics using calibrated freezers with IoT sensors maintained ultra cold temperatures for mRNA vaccines. Continuous alerts enabled staff to correct deviations quickly, reducing spoilage and ensuring uninterrupted immunisation.
Which Regulations Govern Pharma Cold Chain Logistics in 2025?
Pharmaceutical cold chain logistics operates within a complex regulatory landscape. Failing to comply with guidelines can result in fines, shipment quarantines or license suspensions. Here are the major frameworks you must understand:
Good Distribution and Manufacturing Practice (PIB/BPF)
GDP and GMP guidelines—issued by bodies like the European Medicines Agency (Ema), NOUS. Food and Drug Administration (FDA) et Organisation mondiale de la santé (OMS)—set standards for temperature control, traceability and training. Key principles include validated equipment, continuous monitoring and risk management.
Loi sur la sécurité de la chaîne d'approvisionnement en médicaments (DSCSA)
Aux États-Unis, le DSCSA requires a fully electronic, interoperable tracking system by Août 27 2025. Wholesale distributors must exchange transaction information, verify product identifiers at the package level and report suspect medicines. Dispensers must also electronically trace products, with deadlines extending to Novembre 2026 for small dispensers.
Other Regional Frameworks
EU GDP/GMP: Annex 11 mandates validated electronic systems and secure data handling.
USP <1079>: Provides guidelines for shipping temperature sensitive products.
IATA/WHO: Set standards for transporting vaccines and dry ice.
NIST & UKAS Calibration: Ensures measurement accuracy of monitoring devices.
EU Clinical Trials Regulation (UE 536/2014): Governs investigational products during trials.
Regulatory Table
| Règlement | Scope & Exigences clés | Implications pour vous |
| DSCSA (NOUS) | Electronic traceability, serialised product identifiers, full data exchange by Aug 27 2025 | Requires interoperable systems and robust data management; non compliance can halt shipments |
| EU GDP/GMP | Validated electronic systems, secure data handling, audit trails | Mandates calibrated equipment, electronic records and user access controls |
| USP <1079> | Guidelines for shipping temperature sensitive products | Supports best practices for packaging, suivi et documentation |
| IATA/WHO | Standards for transporting vaccines and dry ice | Ensures safe air transport and global consistency |
| NIST/UKAS | Calibration of devices to recognised standards | Ensures measurement accuracy for temperature monitoring |
Compliance Tips
Review upcoming DSCSA deadlines and assess whether your systems meet interoperability requirements.
Map your operations to identify which regional guidelines apply; adapt processes accordingly.
Create a compliance checklist covering calibration, surveillance, documentation et formation.
Partner with validated vendors. Work with suppliers who provide documentation for audits.
Upgrade electronic systems to maintain secure data, audit trails and user access controls.
Exemple du monde réel: A U.S. wholesale distributor modernised its warehouse management system to meet DSCSA requirements. By August 2025 it had integrated serialisation, digital documentation and secure user access, avoiding shipment delays and penalties.
Emerging Technologies Transforming Pharma Cold Chain Logistics
Digital tools and hardware are reshaping cold chain logistics in 2025, enhancing visibility, control and efficiency.
IoT Enabled Sensors and Real Time Monitoring
Internet of Things devices—such as smart tapes, sensors and GPS trackers—collect data on temperature, humidité et localisation en temps réel. When sensors detect unsafe conditions, they send alerts via text or email, activer une action corrective immédiate. IoT sensors with GPS provide end to end visibility, and predictive analytics can reduce unplanned equipment downtime by up to 50 % and repair costs by 10–20 %.
Intelligence artificielle (IA) and Predictive Analytics
AI algorithms analyse historical and real time data to optimise shipping routes, prévoir la demande et prévoir les pannes d’équipement. AI powered route optimisation considers traffic and weather conditions, reducing transit time and quality degradation. Studies indicate AI improves decision making and reduces costs across the cold chain.
Blockchain for End to End Traceability
Blockchain creates a tamper proof ledger linking every transaction chronologically. In the pharmaceutical cold chain it ensures data integrity, prevents manipulation and enhances compliance. Real time temperature logs, shipment times and custody data can be shared securely among stakeholders. This transparency builds trust and simplifies audits.
Solar Powered and Sustainable Cold Storage
Unreliable power grids and rising energy costs have spurred solar powered cold storage units. Solar installations reduce total energy costs—utility rates average 13.10 centimes par kWh while commercial solar can cost 3.2–15,5 centimes par kWh. Sustainable packaging such as recyclable containers and biodegradable wraps also reduces environmental impact.
Automatisation et robotique
Les installations de stockage frigorifique adoptent des systèmes automatisés de stockage et de récupération (AS/RS) and robotic handling to address labour shortages and improve efficiency. Robots minimise human error and operate without breaks, increasing throughput. Environ 80 % of warehouses remain unautomated, leaving room for growth.
Portable Cryogenic Freezers and Modular Ultra Cold Storage
Advanced therapies require ultra cold temperatures. Les congélateurs cryogéniques portables maintiennent –80 °C à –150 °C conditions and provide real time tracking and warning notifications. Modular units allow facilities to scale capacity quickly and accommodate multiple temperature zones.
Innovation Summary Table
| Technologie | Avantages clés | Ce que cela signifie pour vous |
| Capteurs IoT & GPS | Real time temperature/location data; automated alerts | Prevents excursions, optimises routes and enhances visibility |
| IA & analyse prédictive | Demande de prévisions, identifies optimal paths | Reduces transit time and preserves product quality |
| Chaîne de blocs | Tamper proof records, secure data sharing | Simplifies audits and strengthens compliance |
| Stockage à énergie solaire | Lower energy costs, remote operation | Enables sustainable cold chain in off grid areas |
| Automation/robotics | Continuous operation, moins d'erreurs | Improves warehouse efficiency and labour utilisation |
| Congélateurs cryogéniques portables | Ultra cold mobility | Supports gene and cell therapies in diverse locations |
Implementation Tips
Install IoT sensors on every shipment to monitor temperature and location.
Use AI enabled route planning to adjust deliveries based on real time traffic and weather.
Adopt blockchain logs for high value or highly regulated products.
Evaluate solar options if your facility faces unreliable power or high energy costs.
Plan for automation to cope with labour shortages and ensure consistency.
Exemple du monde réel: A Southeast Asian logistics provider deployed blockchain and IoT sensors to monitor vaccine shipments. By sharing real time temperature and humidity logs with all stakeholders, the system eliminated data manipulation and improved regulatory compliance.
Selecting Packaging and Equipment for Pharma Cold Chain Logistics
Effective cold chain management requires more than refrigerators. Packaging and equipment must preserve product integrity during manufacturing, storage and transport. Conteneurs isolés, expéditeurs de palettes, phase change materials and cryogenic units each offer unique benefits.
Options d'emballage
Insulated containers and liners: Represent about 40 % of the cold chain packaging market. They maintain temperature stability for 96 hours or more and can be reusable.
Expéditeurs de palettes: Designed for large volume shipments, they account for roughly 25 % of the market and can integrate smart sensors.
Matériaux à changement de phase (PCMS) and gel packs: Provide precise temperature control by absorbing or releasing latent heat; custom PCMs exist for frozen (–20 ° C), réfrigéré (+5 °C) et ambiant (+22 °C) conditions【542920472744014†L511-L448】.
Panneaux d'isolation sous vide (Vips): Offer superior insulation and thermal stability and can be custom shaped.
Cryogenic shippers and LN2 vapour shippers: Maintenir –80 °C to –190 °C for gene and cell therapies.
Smart packaging platforms: Combine AI and IoT to recommend packaging and track temperature in real time.
Reusable vs Single Use Packaging
Reusable systems reduce total cost of ownership and environmental impact; the market for reusable temperature controlled packaging reached NOUS $2.5 milliards en 2024 and is expected to double by 2033. Single use options may be necessary for regulatory reasons or when return logistics are impractical. Lors du choix de l'emballage, consider route duration, seasonal temperatures and sustainability goals.
Equipment Considerations
Medical grade refrigerators/freezers: Provide uniform temperature and microprocessor controls with alarms.
Congélateurs ultra bas: Required for biologics and gene therapies; ensure redundancy and backup power.
IoT enabled shippers and data loggers: Offer continuous temperature and location data; calibrer régulièrement.
Backup generators and redundant power: Ensure temperature stability during outages.
Packaging Selection Table
| Solution | Temperature Range Supported | Use Cases | Avantages |
| Conteneurs isolés (PPE, VIP) | 2–8 ° C, –20 ° C, –80 °C (with appropriate refrigerants) | Expéditions de vaccins, biologique, insuline | Léger, réutilisable, custom sizes; maintain temperature for 96 h or more |
| Expéditeurs de palettes | 2–8 ° C, –20 ° C, cryogenic with dry ice | Large volume distribution, international transport | Temps de maintien longs; durable; can integrate smart sensors |
| PCM & packs de gel | Gammes spécifiques (–20 ° C, +5 °C, +22 °C) | Envois mixtes, essais cliniques | Contrôle précis de la température; réutilisable; safe for dry ice restrictions |
| Congélateurs cryogéniques & LN2 vapour shippers | –80 °C to –190 °C | Cell and gene therapy, tissue engineering | Maintain viability of living cells; require specialised handling |
| Emballage intelligent | All ranges; dynamic | High value biologics, livraisons à distance | Data integration, route optimisation; reduces packaging errors |
User Level Tips
Conduct thermal validation of packaging for specific routes and conditions.
Pre condition refrigerants (packs de gel, PCMS) to the correct temperature before packing.
Avoid mid route repacking; each opening introduces risk.
Use data loggers and GPS trackers to document temperature throughout transit.
Envisagez des systèmes réutilisables for regular routes to reduce costs and waste.
Exemple du monde réel: A biotech firm shipping a gene therapy used cryogenic LN₂ vapour shippers with IoT sensors. These containers maintained –150 °C depuis plus 120 heures and provided real time data, enabling proactive interventions and avoiding product loss.
Building a Compliant and Resilient Pharma Cold Chain System
A robust cold chain extends beyond equipment; it relies on processes, people and risk management. The table below summarises core components across the pharmaceutical cold chain.
Core Components Across the Cold Chain
| Scène | Activités clés | Plage de température typique | Implications pratiques |
| Fabrication | Maintain specified temperatures for raw materials and finished products; document them for tech transfer | 2–8 °C for most biologics; –20 °C or lower for gene therapies | Ensures ingredients remain stable and prevents degradation before packaging |
| Stockage | Use refrigerators, cold rooms and warehouses with continuous monitoring and alarms | 2–8 ° C (réfrigéré) or lower for ultra cold products | Protects inventory; temperature logs support audits and recalls |
| Transport | Employ refrigerated vehicles and insulated packaging; data loggers track conditions in transit | Usually 2–8 °C; dry ice or liquid nitrogen for cryogenic transport | Minimises risk during delivery; documents chain of custody |
| Distribution | Wholesalers and pharmacies use controlled facilities until dispensing | Same as storage | Ensures final product quality and prevents waste |
Best Practice Checklist
Valider l'équipement: Confirm refrigerators, freezers and data loggers meet GMP/GDP standards and calibrate them regularly.
Mettre en œuvre une surveillance continue: Use IoT devices and alarm systems to track temperature and humidity in real time.
Maintain robust documentation: Record temperature data, calibration certificates and handling procedures; consider blockchain for tamper proof records.
Former le personnel: Provide comprehensive training on GDP requirements, equipment operation and emergency response.
Élaborer des plans d’urgence: Prepare backup power sources, alternative routes and protocols for transferring products to secondary storage.
Conduct risk assessments: Identify potential failures (pannes de courant, vehicle breakdowns, extreme weather) and mitigate them with redundancy and predictive tools.
Auditer régulièrement: Include internal and external audits to verify compliance and uncover gaps.
Interactive Self Assessment Tool
Engage your team by adding a Cold Chain Readiness Quiz. Ask questions like:
Do you know the correct storage temperature for each product?
Are your refrigerators and freezers calibrated within the last year?
Do you use real time monitoring with alerts?
Do you have documented SOPs for packing and handling?
Is there a contingency plan for power failures or transit delays?
A scoring system can highlight weak areas and direct users to resources or services for improvement. Par exemple, a regional pharmacy chain implemented a quarterly self assessment and achieved a 30 % réduction des excursions de température dans les six mois.
2025 Developments and Trends in Pharma Cold Chain Logistics
The pharmaceutical cold chain is evolving rapidly due to new therapies, rising consumer expectations and sustainability mandates.
Présentation des tendances
Automatisation et robotique: Cold storage facilities deploy robots to address labour shortages and improve consistency.
Durabilité: Réfrigération économe en énergie, renewable energy and recyclable packaging are becoming industry standards. Sustainable practices help reduce carbon footprints—cold chain infrastructure accounts for around 2 % des émissions mondiales de CO₂.
Visibilité de bout en bout: Advanced tracking systems provide real time location and temperature data. The hardware segment led the cold chain tracking and monitoring market in 2022, retenir 76.4 % de la part de marché.
Infrastructure modernisation: Upgrades in insulation, refrigeration systems and on site renewable power are essential to meet efficiency and compliance demands.
IA et analyse prédictive: L'IA optimise les itinéraires, prévoit la demande et prédit les pannes d’équipement; demand forecasting addresses uncertainty in supply chains.
Growth in pharma cold chain: The rising demand for temperature sensitive pharmaceuticals and biologics is a key driver. Environ 20 % of new drugs in development are gene and cell based therapies requiring cold chain logistics. The global pharmaceutical cold chain market is expected to reach NOUS $1,454 milliards 2029, avec un TCAC de 4.71 % depuis 2024 à 2029.
Sustainability and green supply chains: Sustainability tops the list at major industry events, with eco friendly materials and renewable energy emphasised. Cold chain operators invest in energy efficient refrigeration and eco friendly refrigerants.
End to end visibility as standard: Full visibility is now required across product recalls, conformité, cold chain integrity and raw material sourcing.
Resilience and risk management: Post COVID 19, supply networks focus on resilience and nearshoring to reduce disruptions. Simulation tools and scenario planning help prepare for unpredictable events.
Derniers progrès réalisés
Rise of biologics and advanced therapies: Sur 40 % de médicaments nouvellement approuvés 2024 étaient des produits biologiques, driving demand for refrigerated and cryogenic storage.
Refrigerated storage growth: Demand for 2–8 °C storage is growing faster than other segments; biologics are projected to grow 6 % TCAC à travers 2035 et vaccins 5 % TCAC. Obesity medications are expected to triple in volume by 2030.
Cold storage market expansion: The global cold storage market (food and pharmaceuticals) devrait croître de NOUS $35.7 milliards en 2025 à NOUS $72 milliards 2033.
Modernisation of warehouses: À propos 80 % of warehouses remain unautomated, offering significant potential for robotics and automation.
High growth for cold chain logistics: The global cold chain logistics market is predicted to grow from NOUS $324.85 milliards en 2024 à NOUS $862.33 milliards 2032 due to demand for biologics and stricter regulations.
Standardisation and integration: Par 2025, 74 % of logistics data is expected to be standardized, permettant une meilleure intégration dans les chaînes d’approvisionnement.
Aperçus du marché et perspectives d’avenir
Therapies are becoming more sophisticated, making temperature controlled logistics a strategic asset. Biologics and personalised medicines are highly sensitive to temperature and frequently require refrigerated storage. Vaccines and rare disease treatments also rely on the 2–8 °C range. Obesity treatments using GLP 1 agonists are fuelling explosive growth in refrigerated volumes. Entre-temps, environmental and ESG pressures push companies to adopt energy efficient refrigeration, renewable power and biodegradable packaging. Strategic partnerships and data standardisation enable better integration across supply chains, improving resilience.
Questions fréquemment posées
Q1: What does pharmaceutical cold chain logistics mean?
It refers to controlling temperature during manufacturing, stockage, transport and distribution of temperature sensitive medicines. The goal is to keep products like vaccines, biologics and gene therapies within specific ranges (Par exemple, 2–8 ° C) to maintain potency and safety.
Q2: How are temperature ranges categorised in the cold chain?
The Healthcare Distribution Alliance classifies four ranges: réfrigéré (2–8 ° C) for insulin and many vaccines; congelé (–20 °C à –40 °C) for DNA and mRNA vaccines; ultralow (–45 °C to –93 °C) for certain vaccines; et cryogénique (–150 °C to –190 °C) pour thérapies cellulaires et géniques. Knowing these categories helps you select suitable equipment and packaging.
Q3: What happens if temperature excursions occur?
Temperature excursions—when products fall outside recommended ranges—are the leading cause of product loss. Jusqu'à 80 % of pharmaceutical losses are attributed to temperature excursions. Excursions degrade drug potency, trigger costly recalls and compromise patient safety. Implement continuous monitoring and contingency plans to mitigate risks.
Q4: How can pharmacies ensure compliance with GDP guidelines?
Pharmacies should use validated equipment, continuous monitoring with real time alerts, robust documentation and regular staff training. They must maintain products within 2–8 °C or other specified ranges, conduct risk assessments and develop contingency plans for power outages or transit delays.
Q5: What new technologies are emerging in 2025 pour la logistique sous chaîne du froid?
Key innovations include IoT sensors for real time monitoring, Optimisation des itinéraires basée sur l'IA, blockchain for tamper proof record keeping, chambre froide à énergie solaire, automation and robotics. Portable cryogenic units and modular ultra cold storage support gene and cell therapies.
Q6: Why is sustainability important in pharmaceutical cold chains?
Cold storage facilities consume large amounts of energy and contribute to carbon emissions. Sustainable practices—such as using renewable energy, energy efficient refrigeration and recyclable packaging—reduce environmental impact and help companies meet regulatory and consumer expectations. Solar powered units can also lower operational costs.
Q7: How will the pharmaceutical cold chain evolve over the next decade?
The next ten years will see rapid growth in 2–8 °C storage, automation and real time visibility. Biologics are projected to grow 6 % TCAC à travers 2035; vaccins 5 %, and obesity medications will triple by 2030. Ultra cold logistics will expand to support cell and gene therapies, while sustainable and modular solutions will become standard.
Résumé et recommandations
Principaux à retenir:
Keep temperatures correct. Understand the specific range for each product and use validated, calibrated equipment to maintain it. Most vaccines and biologics require 2–8 °C, while gene and cell therapies need –80 °C to –150 °C.
Suivre la réglementation. Adhere to GDP/GMP guidelines, prepare for DSCSA electronic traceability by Aug 27 2025, and comply with regional standards.
Embrace technology. Capteurs IoT, AI analytics and blockchain improve visibility, optimise routes and ensure tamper proof records.
Select appropriate packaging. Utiliser des conteneurs isothermes, expéditeurs de palettes, PCMs or cryogenic units based on temperature requirements and route duration.
Train and plan. Educate staff on cold chain protocols, maintain detailed documentation and develop contingency plans for emergencies.
Prioriser la durabilité. Invest in energy efficient refrigeration, renewable power and recyclable packaging.
Action Recommendations:
Assess your cold chain readiness. Conduct a self assessment to identify gaps in equipment, surveillance, documentation et formation. Score results to prioritise improvements.
Upgrade monitoring infrastructure. Implement IoT sensors and AI enabled analytics to achieve real time visibility and predictive insights.
Create a DSCSA compliance roadmap. Plan for electronic traceability, serialisation and secure user access by August 27 2025.
Optimise packaging and transport. Choose reusable insulated containers or cryogenic shippers as needed; validate thermal performance for your routes.
Investir dans la durabilité. Explore solar powered storage, energy efficient refrigeration and recyclable packaging to reduce costs and environmental impact.
Collaborer avec des experts. Partner with 3PL/4PL providers and packaging specialists who understand pharmaceutical regulations and offer end to end visibility.
À propos du tempk
À Rotation, we specialise in cold chain packaging and temperature control solutions for pharmaceuticals. With an in house R&D centre and stringent quality control, we design and manufacture insulated boxes, packs de gel, pallet covers and reusable packaging tailored for 0–10 °C, sub 10 °C and ultra cold ranges. Our validated systems help clients comply with GDP/GMP requirements while reducing waste and supporting sustainability goals. We prioritise eco friendly materials and innovative designs to keep your shipments safe and efficient in 2025.
Appel à l'action: Ready to strengthen your pharma cold chain? Contact Tempk for customised solutions and expert guidance on building a resilient, sustainable cold chain system.
